JP2024532733A5 - - Google Patents
Info
- Publication number
- JP2024532733A5 JP2024532733A5 JP2024507878A JP2024507878A JP2024532733A5 JP 2024532733 A5 JP2024532733 A5 JP 2024532733A5 JP 2024507878 A JP2024507878 A JP 2024507878A JP 2024507878 A JP2024507878 A JP 2024507878A JP 2024532733 A5 JP2024532733 A5 JP 2024532733A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- fluoro
- pyrido
- pyrrolidine
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231543P | 2021-08-10 | 2021-08-10 | |
| US63/231,543 | 2021-08-10 | ||
| US202163289578P | 2021-12-14 | 2021-12-14 | |
| US63/289,578 | 2021-12-14 | ||
| US202263299667P | 2022-01-14 | 2022-01-14 | |
| US63/299,667 | 2022-01-14 | ||
| PCT/US2022/039969 WO2023018810A1 (en) | 2021-08-10 | 2022-08-10 | Heterocyclic compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532733A JP2024532733A (ja) | 2024-09-10 |
| JP2024532733A5 true JP2024532733A5 (https=) | 2025-08-19 |
Family
ID=85200999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024507878A Pending JP2024532733A (ja) | 2021-08-10 | 2022-08-10 | 複素環式化合物及び使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240417412A1 (https=) |
| EP (1) | EP4384177A4 (https=) |
| JP (1) | JP2024532733A (https=) |
| AU (1) | AU2022325858A1 (https=) |
| CA (1) | CA3228338A1 (https=) |
| MX (1) | MX2024001824A (https=) |
| TW (1) | TW202317566A (https=) |
| WO (1) | WO2023018810A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| EP4291199A4 (en) * | 2021-02-09 | 2025-06-18 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| US20240116951A1 (en) * | 2022-05-04 | 2024-04-11 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2023215802A1 (en) * | 2022-05-04 | 2023-11-09 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2023213269A1 (en) * | 2022-05-06 | 2023-11-09 | Zai Lab (Shanghai) Co., Ltd. | Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof |
| CA3247639A1 (en) | 2022-05-06 | 2023-11-09 | PAQ Therapeutics Inc. | CHIMERAS TARGET KRAS-G12D PROTEOLYSIS |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025038936A1 (en) | 2023-08-17 | 2025-02-20 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| CN121941690A (zh) | 2023-10-03 | 2026-04-28 | Paq医疗公司 | Kras蛋白水解靶向嵌合体 |
| TW202529804A (zh) | 2023-10-06 | 2025-08-01 | 美商安進公司 | 用於癌症治療的組合療法 |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070032493A1 (en) * | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
| AU2018273356B2 (en) * | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3908283A4 (en) * | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| EP4048671B1 (en) * | 2019-10-24 | 2026-03-18 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| JP2023553492A (ja) * | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
-
2022
- 2022-08-10 CA CA3228338A patent/CA3228338A1/en active Pending
- 2022-08-10 MX MX2024001824A patent/MX2024001824A/es unknown
- 2022-08-10 US US18/695,688 patent/US20240417412A1/en active Pending
- 2022-08-10 JP JP2024507878A patent/JP2024532733A/ja active Pending
- 2022-08-10 WO PCT/US2022/039969 patent/WO2023018810A1/en not_active Ceased
- 2022-08-10 EP EP22856567.7A patent/EP4384177A4/en active Pending
- 2022-08-10 TW TW111130093A patent/TW202317566A/zh unknown
- 2022-08-10 AU AU2022325858A patent/AU2022325858A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024532733A5 (https=) | ||
| JP2024532735A5 (https=) | ||
| JP2024532734A5 (https=) | ||
| JP2025508703A5 (https=) | ||
| JP2024517695A5 (https=) | ||
| AU2019240299B2 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
| JP2024532733A (ja) | 複素環式化合物及び使用方法 | |
| JP2024532734A (ja) | 複素環式化合物及び使用方法 | |
| RU2019120986A (ru) | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 | |
| AU2015296322B2 (en) | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof | |
| ES2974334T3 (es) | Inhibidores heterocíclicos de ATR cinasa | |
| JP2024071370A (ja) | 大環状ｋｒａｓ阻害剤及び使用方法 | |
| EP3875078A1 (en) | Compounds for the treatment of covid-19 | |
| TWI878423B (zh) | 環狀化合物及其使用方法 | |
| JP2022527796A5 (https=) | ||
| TW201011021A (en) | Imidazopyridin-2-one derivative | |
| WO2016203404A1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| JP2005526072A5 (https=) | ||
| EP3274344A1 (en) | Formylated n-heterocyclic derivatives as fgfr4 inhibitors | |
| EP3571207A1 (en) | Substituted dihydroimidazopyridinediones as mknk1 and mknk2 inhibitors | |
| EP2951175A1 (en) | Substituted pyrazolopyrimidinylamino-indazoles | |
| AU2015366417A1 (en) | Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors | |
| EP3019505A1 (en) | Substituted pyrazolo-pyridinamines | |
| JP2019504102A5 (https=) | ||
| JP2024505890A (ja) | がん、自己免疫及び炎症性障害の治療に有用な三環式化合物 |